New Study to Map Gastric Emptying in GLP-1 Agonist Users
Background
The GLP-1 receptor agonists (like semaglutide) are highly effective for managing type 2 diabetes and obesity by slowing gastric emptying, which helps control blood sugar and promotes satiety. However, the precise kinetics of this effect, especially with different meal compositions and the necessary fasting duration for medical procedures, are not fully understood. This study aims to quantify gastric emptying rates using ultrasound in healthy individuals and assess stomach emptiness in GLP-1 agonist users after a clear liquid diet.
Results
As this study is NOT_YET_RECRUITING and is scheduled to start in 2025, no actual findings are available yet. However, the study is designed to answer two critical questions. It seeks to determine if gastric emptying kinetics after a high-fat breakfast (avocado and eggs) are significantly different from a standard, non-high-fat meal. Furthermore, it will investigate whether an 18-24 hour clear liquid diet is sufficient to achieve an empty stomach, as assessed by ultrasound, in patients actively using GLP-1 agonists. This is crucial for pre-procedural fasting guidelines. The primary objective is to establish whether an 18-24 hour clear liquid diet reliably leads to an empty stomach in GLP-1 agonist users, a finding with significant clinical implications.
Why It Matters
Understanding the precise gastric emptying kinetics in both healthy individuals and GLP-1 agonist users is critically important for optimizing treatment strategies and patient safety. The findings could lead to updated clinical guidelines for fasting protocols before surgeries or endoscopic procedures for patients on these medications, potentially preventing complications like aspiration. This research will provide valuable data to inform healthcare providers on how to best manage patients with type 2 diabetes and obesity who are using GLP-1 agonists, particularly concerning dietary recommendations and pre-procedural preparation. The results will guide future Phase II and III trials focusing on patient management in real-world clinical settings.